National Centre for Pharmacoeconomics

National Centre for

NCPE Ireland

Autologous anti-CD19-transduced CD3+ cells (Tecartus®). HTA ID: 21005

Autologous anti-CD19-transduced CD3+ cells (Tecartus®) is indicated for the treatment of adult patients with relapsed or refractory mantle cell lymphoma after two or more lines of systemic therapy including a Bruton’s tyrosine kinase inhibitor.


NCPE Assessment Process Complete
Rapid review commissioned 03/03/2021
Rapid review completed 22/03/2021
Rapid Review outcome A full HTA is recommended to assess the clinical effectiveness and cost effectiveness of autologous anti-CD19-transduced CD3+ cells compared with the current standard of care